In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
about
Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malariaeditAntimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR NetworkAntimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertaintiesThe interplay between drug resistance and fitness in malaria parasitesA genome wide association study of Plasmodium falciparum susceptibility to 22 antimalarial drugs in KenyaTemporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in UgandaTemporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal KenyaTemporal changes in Plasmodium falciparum anti-malarial drug sensitivity in vitro and resistance-associated genetic mutations in isolates from Papua New GuineaDeclining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coastGenome wide adaptations of Plasmodium falciparum in response to lumefantrine selective drug pressureThe role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011Molecular Mechanisms for Drug Hypersensitivity Induced by the Malaria Parasite's Chloroquine Resistance TransporterMicrobial genomics and antimicrobial susceptibility testing.Molecular surveillance of Plasmodium falciparum drug resistance in the Republic of Congo: four and nine years after the introduction of artemisinin-based combination therapy.Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine Exert Inverse Selective Pressure on Plasmodium Falciparum Drug Sensitivity-Associated Haplotypes in Uganda.In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy changeHigh throughput resistance profiling of Plasmodium falciparum infections based on custom dual indexing and Illumina next generation sequencing-technology.Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, SenegalSelection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina FasoSurveillance of artemether-lumefantrine associated Plasmodium falciparum multidrug resistance protein-1 gene polymorphisms in TanzaniaComparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan childrenIn vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter geneIn vitro antimalarial susceptibility and molecular markers of drug resistance in Franceville, GabonPrevalence of resistance associated polymorphisms in Plasmodium falciparum field isolates from southern Pakistan.Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisininEffectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective studySimilar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial.In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso.Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine.The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, KenyaAssessment of molecular markers for anti-malarial drug resistance after the introduction and scale-up of malaria control interventions in western Kenya.Temporal and seasonal changes of genetic polymorphisms associated with altered drug susceptibility to chloroquine, lumefantrine, and quinine in Guinea-Bissau between 2003 and 2012Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model.Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites.Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda.Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children.Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America.Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina FasoEx vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum.
P2860
Q21032449-B78DF50C-F911-4720-9F5C-78E3C0D9AE4DQ26799713-99A375EB-5C83-4C61-A99E-8EF4D4788328Q26866187-E5251515-7CA3-42EC-9572-43275D5D5343Q26998596-F37E2CE9-CB94-4767-AE8A-AA4E37477593Q28031418-2A366174-BC7E-4C4A-A754-8372E098B18FQ28125904-5C443EA7-C77C-45F3-BA6B-B6C9942AC1DEQ28125914-606A495F-6852-4520-8456-92AAE705F467Q28125917-5F168055-4440-44BE-8612-0FC28BD9750DQ28477892-C5D5D8B1-621C-42AF-8C1E-758DF35D5E9FQ28481274-9AA0D6DF-2D92-42E6-83C7-096D93EEE649Q28487960-1DCBC8A2-F7E6-446C-A860-413482B02F8DQ28552775-D56A0F78-9C8A-473C-9315-2B30E168C97BQ30397574-88CB5D3A-0CCB-45F9-B9AA-A1240BB7D471Q33576812-391DC0EF-2AA7-467C-A2E9-5CCA90684705Q33629027-280ABF28-C166-43DE-BDB5-BF9653CE3E6AQ33676088-83ACC288-DC2F-4C41-BA78-54F67E008413Q33726272-7FC8A1BE-04F0-46F2-AF4E-B0D270BE940DQ33729200-DB7DB1B1-164C-4B98-A785-C83DC81AB7E3Q33802071-AF6204A6-E42A-41DB-9D4A-D714B7223907Q33826359-2A5F1FC4-5634-44A8-9039-9CABAD36A493Q33905089-5755D077-5EC3-4FB9-A0AE-B995A98E9206Q33947834-13F2C0DC-6684-4E6C-942B-E18D7D3D1DE8Q34478084-660FE6D2-B13D-440C-84B4-635FC377EB5EQ34478362-2DD68B03-45E6-4718-88CD-4C63241EEC27Q34569732-E936FCC0-24BA-4FFF-A7AC-9CEEA81595CEQ34597550-BBAE3EB8-5D7A-42C3-AB54-05FA2B7FF35FQ34728230-25BA09FD-1DDE-435A-B6A2-14226A9A27B7Q34910448-23DD4BB4-96BD-4617-93F9-B6311CABD5CEQ34923315-1D7620DF-C6EB-4982-8E6C-5A5483AACBD1Q35068138-30D89A45-0FE0-499D-9D86-23850F4931DFQ35076843-61D2A892-55A3-427E-9B66-2B8635B887B8Q35092092-39E1052F-1E14-4907-AF83-249B5B788E1DQ35105975-7D3C9C68-F2CB-4D36-898D-9AC4B50F8851Q35107675-DFAB1A23-2CDD-4A42-B7FA-D328BFC2C606Q35139505-F754FB13-821C-4D64-B099-CD033A9E9F8AQ35188480-EAB51380-F51D-43B6-9A53-E51BE4AD01D7Q35607844-9F47A350-FB87-47D8-BFA0-CA519AA53BB0Q35698213-597A6B2A-0545-4B84-BA55-D0C54DA1DFC2Q35760573-76DA02F2-A611-4FB7-A538-290CB25A82A2Q35834198-876C3B35-0199-47FD-AA7E-5B91B951672D
P2860
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
In vitro activities of piperaq ...... morphisms in pfcrt and pfmdr1.
@en
type
label
In vitro activities of piperaq ...... morphisms in pfcrt and pfmdr1.
@en
prefLabel
In vitro activities of piperaq ...... morphisms in pfcrt and pfmdr1.
@en
P2093
P2860
P921
P356
P1476
In vitro activities of piperaq ...... morphisms in pfcrt and pfmdr1.
@en
P2093
Abdi Abdirahman
Abdi Diriye
Alexis Nzila
Anja Rippert
Steven M Kiara
P2860
P304
P356
10.1128/AAC.00638-09
P407
P577
2009-09-21T00:00:00Z